Literature DB >> 19400899

Establishing the incidence and prevalence of clinician-diagnosed allergic conditions in children and adolescents using routinely collected data from general practices.

Y S Punekar1, A Sheikh.   

Abstract

BACKGROUND: There remains a need to better characterize the epidemiology of allergic disorders, particularly in relation to describing the incidence, natural history and co-morbidity of allergic conditions.
OBJECTIVES: To estimate the incidence and prevalence of clinician-diagnosed eczema, asthma and rhinitis, alone and in combination, in children and adolescents in the United Kingdom.
METHODS: Using the national General Practice Research Database (GPRD) - one of the largest validated databases of routinely collected healthcare data in the world aggregating 3.6 million individuals - we constructed a retrospective birth cohort of 43,473 children born in the year 1990 and registered with a UK general practice within a year of birth. The cohort was followed until 2008 or the longest available follow-up period to determine the cumulative and age-specific incidence and prevalence rates of clinician-diagnosed eczema, asthma and rhinitis, and an 18-year prevalence of these conditions, alone and in combination.
RESULTS: Eczema had the highest incidence density of 226.9 per 10,000 person-years [95% confidence interval (CI): 225.8-228.0] followed by asthma [136.6;(95% CI: 135.7-137.5)] and rhinitis [61.4;(95% CI: 60.8-62.0)], by the age of 18 years. The incidence densities of suffering from one, two or all three allergic conditions were 323.2 (95% CI: 322.0-324.4), 206.4 (95% CI: 205.7-207.1) and 141.9 (95% CI: 141.4-142.4) per 10,000 person-years, respectively. Among the 24 112 children with a complete 18-year follow-up, eczema had the highest 18-year prevalence of clinician-diagnosed condition at 36.5% (95% CI: 35.9-37.2%) followed by asthma [22.9;(95% CI: 22.3-23.4%)] and rhinitis[11.4;(95% CI: 11.0-11.8%)]. The 18-year prevalence of more than one and all three conditions was 16.1% (95% CI: 15.6-16.6%) and 2.5% (95% CI: 2.4-2.8%), respectively.
CONCLUSIONS: This is one of the first studies to provide national estimates on the age-specific incidence and age-specific prevalence of the major allergic disorders showing clinician-diagnosed eczema, asthma and rhinitis to have high incidence rates in early childhood. A significant proportion of children experience and are diagnosed with multiple allergic conditions in early childhood.

Entities:  

Mesh:

Year:  2009        PMID: 19400899     DOI: 10.1111/j.1365-2222.2009.03248.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  28 in total

Review 1.  Developments in the field of allergy in 2009 through the eyes of Clinical and Experimental Allergy.

Authors:  H W Chu; C M Lloyd; W Karmaus; P Maestrelli; P Mason; G Salcedo; J Thaikoottathil; A J Wardlaw
Journal:  Clin Exp Allergy       Date:  2010-11       Impact factor: 5.018

Review 2.  Telehealthcare for asthma: a Cochrane review.

Authors:  Susannah McLean; David Chandler; Ulugbek Nurmatov; Joseph Liu; Claudia Pagliari; Josip Car; Aziz Sheikh
Journal:  CMAJ       Date:  2011-07-11       Impact factor: 8.262

3.  Vaccination status and health in children and adolescents: findings of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS).

Authors:  Roma Schmitz; Christina Poethko-Müller; Sabine Reiter; Martin Schlaud
Journal:  Dtsch Arztebl Int       Date:  2011-02-18       Impact factor: 5.594

4.  Epidemiology and disease burden from allergic disease in Scotland: analyses of national databases.

Authors:  C Anandan; R Gupta; C R Simpson; C Fischbacher; A Sheikh
Journal:  J R Soc Med       Date:  2009-10       Impact factor: 5.344

Review 5.  Does exposure to indoor allergens contribute to the development of asthma and allergy?

Authors:  S Hasan Arshad
Journal:  Curr Allergy Asthma Rep       Date:  2010-01       Impact factor: 4.806

6.  Estimating the prevalence of aero-allergy and/or food allergy in infants, children and young people with moderate-to-severe atopic eczema/dermatitis in primary care: multi-centre, cross-sectional study.

Authors:  Sangeeta Dhami; Aziz Sheikh
Journal:  J R Soc Med       Date:  2015-01-07       Impact factor: 5.344

Review 7.  Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness.

Authors:  David Price; Alison Chisholm; Thys van der Molen; Nicolas Roche; Elizabeth V Hillyer; Jean Bousquet
Journal:  Curr Allergy Asthma Rep       Date:  2011-12       Impact factor: 4.806

Review 8.  Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies.

Authors:  Ivette A G Deckers; Susannah McLean; Sanne Linssen; Monique Mommers; C P van Schayck; Aziz Sheikh
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

Review 9.  Telehealthcare for asthma.

Authors:  Susannah McLean; David Chandler; Ulugbek Nurmatov; Joseph Liu; Claudia Pagliari; Josip Car; Aziz Sheikh
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

10.  EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.

Authors:  Moises A Calderon; Pascal Demoly; Roy Gerth van Wijk; Jean Bousquet; Aziz Sheikh; Anthony Frew; Glenis Scadding; Claus Bachert; Hans J Malling; Rudolph Valenta; Beatrice Bilo; Antonio Nieto; Cezmi Akdis; Jocelyne Just; Carmen Vidal; Eva M Varga; Emilio Alvarez-Cuesta; Barbara Bohle; Albrecht Bufe; Walter G Canonica; Victoria Cardona; Ronald Dahl; Alain Didier; Stephen R Durham; Peter Eng; Montserrat Fernandez-Rivas; Lars Jacobsen; Marek Jutel; Jörg Kleine-Tebbe; Ludger Klimek; Jan Lötvall; Carmen Moreno; Ralph Mosges; Antonella Muraro; Bodo Niggemann; Giovanni Pajno; Giovanni Passalacqua; Oliver Pfaar; Sabina Rak; Gianenrico Senna; Gabriela Senti; Erkka Valovirta; Marianne van Hage; Johannes C Virchow; Ulrich Wahn; Nikolaos Papadopoulos
Journal:  Clin Transl Allergy       Date:  2012-10-30       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.